Lifestyle Asset Management Inc. Purchases 280 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Lifestyle Asset Management Inc. grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.1% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 4,197 shares of the company’s stock after buying an additional 280 shares during the quarter. Medpace accounts for 0.7% of Lifestyle Asset Management Inc.’s holdings, making the stock its 25th biggest position. Lifestyle Asset Management Inc.’s holdings in Medpace were worth $1,279,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Barclays PLC increased its stake in shares of Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after purchasing an additional 8,275 shares during the last quarter. Chicago Partners Investment Group LLC purchased a new stake in shares of Medpace during the 4th quarter worth approximately $298,000. Meritage Portfolio Management increased its stake in shares of Medpace by 4.6% during the 4th quarter. Meritage Portfolio Management now owns 3,211 shares of the company’s stock worth $1,067,000 after purchasing an additional 142 shares during the last quarter. Financial Advocates Investment Management purchased a new stake in shares of Medpace during the 4th quarter worth approximately $423,000. Finally, Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in shares of Medpace during the 4th quarter worth approximately $532,000. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

MEDP opened at $312.74 on Thursday. The company has a fifty day moving average price of $298.32 and a 200-day moving average price of $324.17. The firm has a market capitalization of $8.99 billion, a P/E ratio of 24.76, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period in the previous year, the business earned $3.20 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Leerink Partners assumed coverage on shares of Medpace in a research note on Monday, March 24th. They issued a “market perform” rating and a $330.00 price objective for the company. Robert W. Baird reduced their price objective on shares of Medpace from $340.00 to $313.00 and set a “neutral” rating for the company in a research note on Wednesday, April 23rd. TD Cowen lowered shares of Medpace from a “buy” rating to a “hold” rating and reduced their price objective for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research note on Monday, March 24th. Finally, William Blair reiterated a “market perform” rating on shares of Medpace in a research note on Tuesday, April 22nd. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $349.30.

Insider Transactions at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares of the company’s stock, valued at approximately $904,856.36. The trade was a 36.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 20.30% of the stock is currently owned by insiders.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.